Share This Page

 
Now on Twitter!

Follow us: ChinaBio

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...
Free White Paper

>>NEW! Download now...
Print

Featured Event...


ChinaBio® Partnering Forum 2012

 May 23-24, 2012 | Suzhou, China

The fourth annual ChinaBio® Partnering Forum is just around the corner. We are expecting more than 700 delegates from all over the world this year. See many of China's leading pharmas including ASK, CTTQ, Fosun, Furen, Hengrui, Hutchison, Luye, Qilu, Reyoung, Simcere, and universities including Fudan, Jiaotong and Tsinghua. Multinationals including Bayer, Astrazeneca, Boehringer Ingleheim, Johnson & Johnson, Life Technologies, Lilly, Lonza, Merck and others will also be in Suzhou seeking strategic alliances and partnerships  making ChinaBio Partnering Forum the event to truly get partnerships started in China.

Bootcamp added on May 22. Find out more.

>> See  www.cbpf2012.com for more information in English or Chinese.

Recent Articles

  The Week in Review: Partnering Bootcamp Leads into ChinaBio® Partnering Forum (in: Week in Review)
May 19, 2012
For the first time, the annual ChinaBio® Partnering Forum, which will be held next week, features a Partnering Bootcamp, a half-day pre-conference program; China National Biotech Group (CNBG), the nation’s biggest biotech company, will stage a $1.6 billion IPO in Hong Kong; Zhejiang Conba Pharma raised $148 million via a private placement; Ningbo David Medical Device completed a $63.5 million IPO on the ChiNext Exchange; Ventac Partners in-licensed potential diabetes 2 treatments from Guangzhou Institute of Biomedicine and Health; Shanxi Zhendong Pharmaceutical Company and the Shanxi College of Traditional Chinese Medicine banded together with the University of Adelaide in Australia to study the molecular basis of TCM; Johnson & Johnson is actively pursuing M&A in China as a way to increase its revenue growth; Bristol-Myers Squibb formed a multi-year strategic partnership with Tsinghua University of Beijing and invested $20 million to expand its China manufacturing capacity; Baxter International received SFDA approval for its recombinant treatment of hemophilia A; Novozymes Biopharma has begun selling hyaluronic acid made at its new Tianjin facility; and Zhejiang Hisun Pharma will manufacture ThermoDox®, a clinical-stage liver cancer drug, for Celsion of the US. More details….

Stock Symbols: (SHA: 600572) (SHE: 300314) (SHE: 300158) (NYSE: JNJ) (NYSE:BMY) (NYSE: BAX) (NSDQ OMX: Copenhagen: NZYM B) (SHA: 600267) (NSDQ: CLSN)

Share this with colleagues:  

  China National Biotech to Raise $1.6 Billion in Hong Kong IPO (in: Deals & Financings)
May 18, 2012
China National Biotech Group (CNBG) expects to raise up to 10 billion RMB ($1.6 billion) in a Hong Kong IPO, according to sources. CNBG is one of many subsidiaries of the sprawling state-owned China National Pharmaceutical Group Corp (Sinopharm). Last November, Zhiping Song, Chairman of the parent company, said the IPO would take place in the first half of 2012, though at the time, he did not reveal the size of the offering. More details....

Share this with colleagues:  

  Ventac Partners In-licenses Diabetes Treatments from Guangzhou Institute (in: Deals & Financings)
May 18, 2012
Ventac Partners has in-licensed potential diabetes 2 treatments from Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences (GIBH). The molecules target the ERR-alpha receptor, which has been shown to affect the body’s ability to respond to insulin. Ventac has placed responsibility for the venture in a new company, CASiGEN Pharma Ltd. CASiGEN will seek investors to advance development of the molecules, and it expects to form a partnership with a mainland China company to bring new diabetes drugs to the China market. More details....

Share this with colleagues:  

  J&J in the Hunt for China Pharma Acquisitions (in: Deals & Financings)
May 17, 2012
Johnson & Johnson is actively pursuing M&A in China as a way of keeping its revenue growth at least equal to the general rise in China’s pharmaceutical market – which J&J estimates to be 17%. J&J is especially interested in companies that would add products to its portfolio of mental health drugs and cancer treatments. Unlike some of its big pharma competitors, the company is not branching out into generic drugs as a way to increase China revenues. More details....

Stock Symbol: (NYSE: JNJ)

Share this with colleagues:  

  Baxter Gains SFDA Approval for Recombinant Hemophilia Treatment (in: Trials & Approvals)
May 17, 2012
Baxter International has received approval from the SFDA of its treatment for hemophilia A, a product known as Advate. Advate is a recombinant human coagulation factor VIII for injection used both for control and prevention of bleeding in individuals with hemophilia A. According to Baxter, more than 50,000 people in China have hemophilia A. More details....

Stock Symbol: (NYSE: BAX)

Share this with colleagues:  

  BMS Ups Investment in China R&D and Manufacturing (in: News & Analysis)
May 16, 2012
Announcing two separate strategic China initiatives yesterday, Bristol-Myers Squibb increased its commitment to building its presence in China and its bid for an increased share of the country’s prescription drug market. On the one hand, BMS formed a multi-year strategic partnership with Tsinghua University of Beijing. BMS will underwrite early-stage research to identify new drug targets in oncology and immunoscience. Meanwhile, with a $20 million investment, BMS will expand its manufacturing capacity at its Shanghai site, allowing the company to produce diabetes drugs in China. More details....

Stock Symbol: (NYSE:BMY)

Share this with colleagues:  

  Novozymes Opens Hyaluronic Acid Plant in Tianjin (in: News & Analysis)
May 16, 2012
Novozymes Biopharma, the pharmaceutical subsidiary of Novozymes A/S, a Swedish maker of industrial enzymes, has begun selling hyaluronic acid that is made at its new Tianjin facility. Novozymes’ HA product is manufactured via a Bacillus-based process, while conventionally produced HA is derived from rooster combs or strains of Streptococcus bacteria. In comparison to its competitors’ HA, Novozymes says its HA is less prone to impurities or viral contamination. More details....

Stock Symbols: (NSDQ OMX: Copenhagen: NZYM B)

Share this with colleagues:  

  Partnering Bootcamp Added to ChinaBio® Partnering Forum (in: News & Analysis)
May 15, 2012
For the first time, a Partnering Bootcamp has been added to the annual ChinaBio® Partnering Forum. The Bootcamp, a half-day pre-conference program sponsored by Cooley LLP, will take place on the afternoon of Tuesday, May 22. The ChinaBio® Partnering Forum is hosted by ChinaBio® LLC, a leading consulting firm in Shanghai, and EBD Group, a leading biopharma event organizer. This year’s Partnering Forum will be held May 23-24 in Suzhou, China. More details....

Share this with colleagues:  

  Hisun Pharma to Supply Celsion’s Proprietary Cancer Drug (in: CRO/CMO Services)
May 15, 2012
Zhejiang Hisun Pharma was chosen to be the commercial supplier of ThermoDox®, a clinical-stage liver cancer drug developed by Celsion of the US. ThermoDox® is Celsion's proprietary liposomal encapsulation of doxorubicin. Hisun positioned the agreement as a step toward developing a portfolio of branded generics products. In February of this year, Hisun announced a $245 million JV with Pfizer, a project also devoted to branded generics. More details.....

Stock Symbols: (SHA: 600267) (NSDQ: CLSN) (NYSE: PFE)

Share this with colleagues:  

  IPO of Ningbo David Medical Device Greeted Warmly (in: Deals & Financings)
May 14, 2012
Ningbo David Medical Device Co. completed its IPO on the ChiNext Exchange on May 7, raising 400 million RMB ($63.5 million). The company placed 20 million shares at a price of 20 RMB each, a price/earnings ratio of 30. After rising to a high of 30 RMB, the stock closed today at 26.13 RMB, a return of 31% for the IPO investors. David Medical Device produces infant warmers and products that treat infant jaundice, along with other products that are used in neonatal units. More details....

Stock Symbol: (SHA: 300314)

Share this with colleagues:  

 
more articles >>
Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Partnering Forum 2012
May 23-24, 2012
Suzhou, China

>>More events...
Partner Events


BioPacific Conference 2012
June 2, 2012
California, USA

  China Forum 2012
  November 11, 2012
Hamburg, Germany

>>More details...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners